 |
市場調査レポート
商品コード
1458098
メタボロミクスの世界市場規模、シェア、成長分析、製品・サービス別、最終用途別 - 産業予測、2024年～2031年Global Metabolomics Market Size, Share, Growth Analysis, By Product and service(Metabolomics Instruments, Separation Tools), By End-use(Academic and Research Institutes, Pharmaceutical & Biotechnology Companies) - Industry Forecast 2024-2031 |
||||||
| メタボロミクスの世界市場規模、シェア、成長分析、製品・サービス別、最終用途別 - 産業予測、2024年～2031年 |
|
出版日: 2024年03月28日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
メタボロミクスの世界市場規模は2022年に28億3,000万米ドルと評価され、予測期間（2024年～2031年）のCAGRは13%で、2023年の32億米ドルから2031年には85億1,000万米ドルに成長する見通しです。
慢性疾患の増加、個別化医療のニーズの高まり、技術の向上などが、世界のメタボロミクス市場の着実な成長に寄与しています。メタボロミクス市場の目標は、科学者や医療専門家が生体システムの根底にある基本的な生化学プロセスを理解できるようなリソースや機器を提供することです。科学者は、細胞が作り出す代謝産物を調べることで、病気の根本的な原因について参考資料を得たり、将来の治療標的の可能性を見つけたりすることができます。病気の診断やオーダーメイド医療のためのバイオマーカーの創出は、メタボロミクスのさらなる用途です。メタボロミクス解析は、核磁気共鳴分光法や質量分析法などの代謝物プロファイリング用のハイスループットプラットフォームの開発により、より迅速かつ正確に行えるようになった。生成されるデータの量と複雑さのため、メタボロミクスデータの解釈は困難な場合があります。慢性疾患の罹患率の上昇、オーダーメイド薬物療法のニーズの高まり、技術の向上が世界のメタボロミクス市場を牽引しています。市場は、機器の高価格、標準の不在、有資格者の不足といった困難に直面しています。メタボロミクス市場には、政府、企業、学術界が協力し、新たなアプリケーションを生み出す見込みがあります。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- セカンダリおよびプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
メタボロミクスの世界市場：製品・サービス別
- 市場概要
- メタボロミクス機器
- 分離ツール
- 検出ツール
メタボロミクスの世界市場：最終用途別
- 市場概要
- 学術研究機関
- 製薬・バイオテクノロジー企業
- 受託研究機関
- その他のエンドユーザー
メタボロミクスの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Agilent Technologies, Inc.（US）
- Thermo Fisher Scientific, Inc.（US）
- Shimadzu Corporation（Japan）
- Waters Corporation（US）
- Bruker Corporation（US）
- PerkinElmer, Inc.（US）
- Danaher Corporation（US）
- Bio-Rad Laboratories, Inc.（US）
- Metabolon, Inc.（US）
- Human Metabolome Technologies, Inc.（Japan）
- Agios Pharmaceuticals, Inc.（US）
- LECO Corporation（US）
- Biocrates Life Sciences AG（Austria）
- Shimazu Europe GmbH（Germany）
- Eurofins Scientific（Luxembourg）
- Molecular Devices, LLC（US）
- Phenomenex, Inc.（US）
- Cambridge Isotope Laboratories, Inc.（US）
- Sciex（US）
- JEOL Ltd.（Japan）
Global Metabolomics Market size was valued at USD 2.83 Billion in 2022 and is poised to grow from USD 3.20 Billion in 2023 to USD 8.51 Billion by 2031, at a CAGR of 13 % during the forecast period (2024-2031).
The increased prevalence of chronic diseases, the growing need for personalized medication, and technological improvements have all contributed to the steady growth of the worldwide metabolomics market. The goal of the metabolomics market is to give scientists and medical professionals resources and instruments that will enable them to comprehend the fundamental biochemical processes that underlie biological systems. Scientists can learn more about the underlying causes of disease and find possible targets for future treatments by examining the metabolites that cells create. The creation of biomarkers for illness diagnosis and tailored medicine are further uses for metabolomics. Metabolomics analysis is now more faster and more accurate thanks to the development of high-throughput platforms for metabolite profiling, such as nuclear magnetic resonance spectroscopy and mass spectrometry. Because of the volume and complexity of the data generated, metabolomics data interpretation can be difficult. The rising incidence of chronic diseases, the growing need for tailored medication, and technological improvements are driving the worldwide metabolomics market. The market faces difficulties such the high price of instruments, the absence of standards, and the scarcity of qualified workers. There are plenty of prospects in the market for government, business, and academic cooperation as well as for the creation of new applications.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Metabolomics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Metabolomics Market Segmental Analysis
The product, application, and geographic segments of the worldwide metabolomics market are divided up. The market is divided into three segments based on the kind of product and service: metabolomics instruments, separation tools, and detection tools. The market is divided into academic and research institutions, pharmaceutical and biotechnology firms, contract research organizations, and others based on the end-use segmentation. The market is divided into five regions: Latin America, Middle East and Africa, Asia Pacific, Europe, and North America.
Drivers of the Global Metabolomics Market
The market has been significantly influenced by the ongoing developments in metabolomics technology, including mass spectrometry, NMR spectroscopy, and data analysis tools. These developments improve metabolomics analysis's sensitivity, accuracy, and throughput, allowing scientists to draw deeper conclusions from metabolomics data.
Restraints in the Global Metabolomics Market
One major obstacle to the market is the high cost of metabolomics devices, consumables, and data analysis tools. The use of metabolomics technology is restricted, especially in environments with limited resources, by the initial cost of setting up metabolomics laboratories and the continuing costs for consumables and maintenance.
Market Trends of the Global Metabolomics Market
Integrating metabolomics data with genomes, proteomics, and transcriptomics data is known as the integration of multi-omics techniques. This integration offers insights into intricate biological processes and the causes of disease, enabling a thorough understanding of biological systems. Systems biology and customized medicine are projected to advance as a result of the integration of multi-omics data.
Application of Metabolomics in Microbiome Research: The study of the metabolic interactions between host organisms and the microbial communities they are linked with is made possible by the growing application of metabolics in microbiome research. Understanding the metabolites generated by the microbiome and how they affect host health and illness is possible through metabolomics. It is anticipated that the use of metabolomics in microbiome research will spur additional advancements in the fields of microbial ecology, tailored nutrition, and gut health.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Metabolomics Market by Product and service
- Market Overview
- Metabolomics Instruments
- Separation Tools
- and Detection Tools
Global Metabolomics Market by End-use
- Market Overview
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- and other End Users
Global Metabolomics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shimadzu Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Waters Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bruker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Metabolon, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Human Metabolome Technologies, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agios Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LECO Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocrates Life Sciences AG (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shimazu Europe GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Molecular Devices, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Phenomenex, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cambridge Isotope Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sciex (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- JEOL Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
